{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:59:56Z","timestamp":1785430796083,"version":"3.56.0"},"reference-count":57,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR grant #7011-16"],"award-info":[{"award-number":["SCOR grant #7011-16"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["5x1000, Special Program Metastases (21198)"],"award-info":[{"award-number":["5x1000, Special Program Metastases (21198)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Core Grant No. P30-CA008748"],"award-info":[{"award-number":["Core Grant No. P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast implant-associated lymphoma (BIA-ALCL) has recently been recognized as an independent peripheral T-cell lymphoma (PTCL) entity. In this study, we generated the first BIA-ALCL patient-derived tumor xenograft (PDTX) model (IL89) and a matching continuous cell line (IL89_CL#3488) to discover potential vulnerabilities and druggable targets. We characterized IL89 and IL89_CL#3488, both phenotypically and genotypically, and demonstrated that they closely resemble the matching human primary lymphoma. The tumor content underwent significant enrichment along passages, as confirmed by the increased variant allele frequency (VAF) of mutations. Known aberrations (JAK1 and KMT2C) were identified, together with novel hits, including PDGFB, PDGFRA, and SETBP1. A deep sequencing approach allowed the detection of mutations below the Whole Exome Sequencing (WES) sensitivity threshold, including JAK1G1097D, in the primary sample. RNA sequencing confirmed the expression of a signature of differentially expressed genes in BIA-ALCL. Next, we tested IL89\u2019s sensitivity to the JAK inhibitor ruxolitinib and observed a potent anti-tumor effect, both in vitro and in vivo. We also implemented a high-throughput drug screening approach to identify compounds associated with increased responses in the presence of ruxolitinib. In conclusion, these new IL89 BIA-ALCL models closely recapitulate the primary correspondent lymphoma and represent an informative platform for dissecting the molecular features of BIA-ALCL and performing pre-clinical drug discovery studies, fostering the development of new precision medicine approaches.<\/jats:p>","DOI":"10.3390\/cancers12061603","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:00:56Z","timestamp":1592478056000},"page":"1603","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-6862","authenticated-orcid":false,"given":"Danilo","family":"Fiore","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-3880","authenticated-orcid":false,"given":"Luca Vincenzo","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"},{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-2024","authenticated-orcid":false,"given":"Paul","family":"Zumbo","sequence":"additional","affiliation":[{"name":"Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-5254","authenticated-orcid":false,"given":"Jude M.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, Weill Cornell Medicine and the New York Presbyterian Hospital, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Systems Biology and Biomedical Informatics, Columbia University, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-8205","authenticated-orcid":false,"given":"Liron","family":"Yoffe","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Di Maggio","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"},{"name":"Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Khodos","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-6375","authenticated-orcid":false,"given":"Joseph","family":"Casano","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Kayembe","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Betel","sequence":"additional","affiliation":[{"name":"Department of Medicine and Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Foa\u2019","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0608-1350","authenticated-orcid":false,"given":"Leandro","family":"Cerchietti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, Weill Cornell Medicine and the New York Presbyterian Hospital, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rabadan","sequence":"additional","affiliation":[{"name":"Department of Systems Biology and Biomedical Informatics, Columbia University, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1097\/PRS.0000000000005567","article-title":"Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants","volume":"143","author":"Collett","year":"2019","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration (FDA) (2020, April 01). Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma, Available online: https:\/\/www.fda.gov\/medical-devices\/breast-implants\/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma.","DOI":"10.46889\/JCMR.2020.1305"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2017.4510","article-title":"Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast","volume":"4","author":"Hauptmann","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cordeiro, P.G., Ghione, P., Ni, A., Hu, Q., Ganesan, N., Galasso, N., Dogan, A., and Horwitz, S.M. (2020). Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J. Plast. Reconstr. Aesthet. Surg.","DOI":"10.1016\/j.bjps.2019.11.064"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jso.25626","article-title":"Breast implant-associated anaplastic large cell lymphoma, a systematic review and in-depth evaluation of the current understanding","volume":"120","author":"Ebner","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/CCO.0000000000000476","article-title":"New insights into breast implant-associated anaplastic large cell lymphoma","volume":"30","author":"Laurent","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/PRS.0000000000003282","article-title":"U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma","volume":"139","author":"Doren","year":"2017","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_9","first-page":"360","article-title":"Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL","volume":"135","author":"Laurent","year":"2020","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","article-title":"Genetic subtyping of breast implant-associated anaplastic large cell lymphoma","volume":"132","author":"Oishi","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36126","DOI":"10.18632\/oncotarget.26308","article-title":"Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma","volume":"9","author":"Blombery","year":"2018","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.3324\/haematol.2016.146118","article-title":"Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma","volume":"101","author":"Blombery","year":"2016","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.14431","article-title":"Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK\/STAT signalling pathway genes, TP53 and DNMT3A","volume":"180","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00428-018-2352-y","article-title":"Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma","volume":"473","author":"Letourneau","year":"2018","journal-title":"Virchows. Arch."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"59S","DOI":"10.1097\/PRS.0000000000005570","article-title":"Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma","volume":"143","author":"Blombery","year":"2019","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_16","first-page":"S14","article-title":"Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)","volume":"39","author":"Oishi","year":"2019","journal-title":"Aesthet. Surg. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"DeRose","year":"2011","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fiore, D., Di Giacomo, F., Kyriakides, P.W., and Inghirami, G. (2017). Patient-Derived-Tumor-Xenograft: Modeling cancer for basic and translational cancer research. Clin. Diagn. Pathol., 1.","DOI":"10.15761\/CDP.1000110"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","article-title":"Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts","volume":"75","author":"Cassidy","year":"2015","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13054","DOI":"10.1038\/srep13054","article-title":"Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells","volume":"5","author":"Sugimoto","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-12-0101","article-title":"Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma","volume":"18","author":"Lechner","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hon.2582","article-title":"Breast implant-associated anaplastic large cell lymphoma and other rare T-cell lymphomas","volume":"37","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fragliasso, V., Verma, A., Manzotti, G., Tameni, A., Bareja, R., Heavican, T.B., Iqbal, J., Wang, R., Fiore, D., and Mularoni, V. (2020). The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK(-) anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia.","DOI":"10.1038\/s41375-020-0754-8"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Siranosian","year":"2018","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/asj\/sjy250","article-title":"What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)","volume":"39","author":"Kadin","year":"2019","journal-title":"Aesthet. Surg. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/asj\/sjy229","article-title":"The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis","volume":"39","author":"Turner","year":"2019","journal-title":"Aesthet. Surg. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"190006","DOI":"10.1098\/rsob.190006","article-title":"Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?","volume":"9","author":"Fitzal","year":"2019","journal-title":"Open Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1096\/fj.201800636R","article-title":"Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression","volume":"33","author":"Brehm","year":"2019","journal-title":"FASEB J."},{"key":"ref_31","first-page":"1631","article-title":"Breast implant-associated ALK-negative anaplastic large cell lymphoma: A case report and discussion of possible pathogenesis","volume":"6","author":"George","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ajpath.2019.09.005","article-title":"Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma","volume":"190","author":"Turner","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41379-018-0130-7","article-title":"Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas","volume":"32","author":"Piccaluga","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ha","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_37","unstructured":"ClinicalTrials.gov (2020, April 01). NCT02974647: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02974647."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-811X-7-17","article-title":"HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells","volume":"7","author":"Schoof","year":"2009","journal-title":"Cell Commun. Signal"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bph.12935","article-title":"YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells","volume":"172","author":"Cheng","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_41","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) (2020, April 01). D\u00e9cision du 02\/04\/2019 portant interdiction de mise sur le march\u00e9, de distribution, de publicit\u00e9 et d\u2019utilisation d\u2019implants mammaires \u00e0 enveloppe macro-textur\u00e9e et d\u2019implants mammaires polyur\u00e9thane, ainsi que retrait de ces produits. Available online: https:\/\/ansm.sante.fr\/Decisions\/Injonctions-decisions-de-police-sanitaire-sanctions-financieres-interdictions-de-publicite-Decisions-de-police-sanitaire\/Decision-du-02-04-2019-portant-interdiction-de-mise-sur-le-marche-de-distribution-de-publicite-et-d-utilisation-d-implants-mammaires-a-enveloppe-macro-texturee-et-d-implants-mammaires-polyurethane-ainsi-que-retrait-de-ces-produits."},{"key":"ref_42","unstructured":"Government of Canada (2020, April 01). Health Canada Advises Allergan of Its Intent to Suspend Its Licences for Biocell Breast. Available online: https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2019\/69520a-eng.php."},{"key":"ref_43","unstructured":"(2020, April 01). Statement from FDA Principal Deputy Commissioner Amy Abernethy and Jeff Shuren, Director of the FDA\u2019s Center for Devices and Radiological Health on FDA\u2019s New Efforts to Protect Women\u2019s Health and Help to Ensure the Safety of Breast Implants, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-principal-deputy-commissioner-amy-abernethy-md-phd-and-jeff-shuren-md-jd-director-fdas."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"30e","DOI":"10.1097\/PRS.0000000000006390","article-title":"Does Breast Implant-Associated ALCL Begin as a Lymphoproliferative Disorder?","volume":"145","author":"Kadin","year":"2020","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_45","unstructured":"(2020, April 01). Cosmic\u2014Catalogue of Somatic Mutation in Cancer. Available online: https:\/\/cancer.sanger.ac.uk\/cosmic\/mutation\/overview?id=96497634."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ajpath.2015.01.016","article-title":"Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements","volume":"185","author":"Delitto","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1073\/pnas.1700682114","article-title":"Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1\/STAT3 mutations","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2008.20.9759","article-title":"Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms","volume":"28","author":"Piva","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: An efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_53","unstructured":"Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/bioinformatics\/btu376","article-title":"ABRA: Improved coding indel detection via assembly-based realignment","volume":"30","author":"Mose","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: Allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic. Acids Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nilsen, G., Liestol, K., Van Loo, P., Moen Vollan, H.K., Eide, M.B., Rueda, O.M., Chin, S.F., Russell, R., Baumbusch, L.O., and Caldas, C. (2012). Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genom., 13.","DOI":"10.1186\/1471-2164-13-591"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ebiom.2018.01.014","article-title":"Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway","volume":"28","author":"Pera","year":"2018","journal-title":"EBioMedicine"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1603\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:39:59Z","timestamp":1760175599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061603"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061603","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]}}}